Abstract
The SARS-Coronavirus-2 (SARS-CoV-2) driven pandemic was first recognized in late 2019, and the first few months of its evolution were relatively clock-like, dominated mostly by neutral substitutions. In contrast, the second year of the pandemic was punctuated by the emergence of several variants that bore evidence of dramatic evolution. Here, we compare and contrast evolutionary patterns of various variants, with a focus on the recent Delta variant. Most variants are characterized by long branches leading to their emergence, with an excess of non-synonymous substitutions occurring particularly in the Spike and Nucleocapsid proteins. In contrast, the Delta variant that is now becoming globally dominant, lacks the signature long branch, and is characterized by a step-wise evolutionary process that is ongoing. Contrary to the “star-like” topologies of other variants, we note the formation of several distinct clades within Delta that we denote as clades A-E. We find that sequences from the Delta D clade are dramatically increasing in frequency across different regions of the globe. Delta D is characterized by an excess of non-synonymous mutations, mostly occurring in ORF1a/b, some of which occurred in parallel in other notable variants. We conclude that the Delta surge these days is composed almost exclusively of Delta D, and discuss whether selection or random genetic drift has driven the emergence of Delta D.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by an ERC starting grant 852223 (RNAVirFitness), and by an Israeli Science Foundation grant 3963/19.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). For the Israel cohort, patient consent was waived as the study used remains of clinical samples and the analysis used anonymous clinical data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵ψ Israel Consortium of SARS-CoV-2 sequencing: Neta S. Zuckerman, Orna Mor, Efrat Dahan Bucris, Michal Mandelboim, Danit Sofer, Dana Bar-Ilan, Miranda Geva, Omer Asraf, Oran Erster, Gideon Rechavi, Efrat Glick-Saar, Nir Rainy, Chen Weiner, Reut Sorek-Abramovich, Yevgeni Yegorov, Anna Vishnevsky, Patricia Benveniste-Lekovitz, Abu Hamad Ramzia, Adina Bar Chaim, Ella Mendelson.
Small corrections and data updates.
Data Availability
All data generated via the Israel Consortium of SARS-CoV-2 sequencing, including the Israel cohort data in this manuscript, is regularly deposited and available in GISAID.
